演題詳細

ポスター / Poster

ポスター 35 (Poster 35) :骨髄腫:症例(レナリドミド)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
和泉 透 (Tohru Izumi):1
1:栃木県立がんセンター 血液内科
 
前へ戻る

Three cases of lenalidomide-resistant myeloma for a response after a switch to BiRd therapy

演題番号 : PS-1-264

黒田 裕行 (Hiroyuki Kuroda):1、山田 充子 (Michiko Yamada):1、定免 渉 (Wataru Jomen):1、吉田 正宏 (Masahiro Yoshida):1、安部 智之 (Tomoyuki Abe):1、櫻井 環 (Tamaki Sakurai):1、藤井 重之 (Shigeyuki Fujii):1、藤田 美悧 (Miri Fujita):2、松野 鉄平 (Teppei Matsuno):3、佐藤 昌則 (Masanori Sato):3、前田 征洋 (Masahiro Maeda):1

1:Dept. of Gastroenterology Hematology/Clinical Oncology, Steel Memorial Muroran Hospital、2:Dept. of Pathology/Clinical Laboratory, Steel Memorial Muroran Hospital、3:Fourth Dept of Internal Medicine, Sapporo Medical University

 

BiRd therapy, combination therapy with lenalidomide (LEN), dexamethasone (DEX), and clarithromycin (CAM; Biaxin), is highly effective for untreated symptomatic myeloma. However, its efficacy against myeloma that has become resistant to treatment for recurrence during combination therapy with LEN and DEX (Ld therapy) remains unclear. We provided BiRd therapy to three patients with IgA myeloma that exacerbated during Ld therapy by adding CAM (400 mg/day) to the Ld therapy. Case 1: A 70-year-old man who first visited our hospital in March 2007 and underwent MP therapy from April 2007. Treatment became ineffective in January 2012, and Ld therapy was initiated. IgA decreased steadily thereafter. Because IgA increased again from June 2012, treatment was switched to BiRd therapy in October 2012. Case 2: An 82-year-old man who underwent MPT therapy from September 2010. The treatment became ineffective in December 2011, and Ld therapy was initiated in January 2012. IgA decreased steadily thereafter. Because IgA increased again from August 2012, treatment was switched to BiRd therapy in September 2012. Case 3: An 84-year-old man who first visited our hospital in February 2012. Ld therapy was given from March 2012, and IgA decreased steadily thereafter. Because IgA increased again from August 2012, treatment was switched to BiRd therapy in September 2012. In all cases, IgA decreased after switching to BiRd therapy, with no exacerbation in terms of hematotoxicity or non-hematotoxicity. BiRd therapy thus may be a therapeutic option for symptomatic myeloma resistant to Ld therapy.

前へ戻る